Xiaoqing Liu

机构：Chinese Academy of Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Chinese PLA General Hospital, Ningbo Institute of Industrial Technology · ORCID：0009-0004-4457-0926

发表论文 96 篇 · 总被引 5252 次 · h-index 21

代表论文

• Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial (2023 · Journal of Thoracic Oncology · 被引 51)
• Comparison study of ultra-high performance geopolymer concrete (UHPGC) and ultra-high performance concrete (UHPC): mechanical properties, durability and carbon emissions (2025 · Composites Part B Engineering · 被引 45)
• MRI-based two-stage deep learning model for automatic detection and segmentation of brain metastases (2023 · European Radiology · 被引 25)
• The Role and Potential Application of IL-12 in the Immune Regulation of Tuberculosis (2025 · International Journal of Molecular Sciences · 被引 20)
• Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial (2023 · Journal of Thoracic Oncology · 被引 16)
• First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 14)